Nurix Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Nurix Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nurix Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nurix Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nurix Therapeutics Inc (Nurix Therapeutics) is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cancer and autoimmune diseases. The company's pipeline products include Bexobrutideg (NX-5948) for chronic lymphocytic leukemia, waldenström macroglobulinemia and non-hodgkin’s lymphoma; Zelebrudomide (NX-2127) which treats B-cell malignancies; NX-1607 targets Immuno-oncology disorders; BRAF degrader for solid tumors; NX 0479/GS 6791 which treats rheumatoid arthritis and other inflammatory diseases; SAR448272/NX-3911 for Type 2 inflammatory diseases. Its proprietary DELigase platform technology to modulate targeted proteins and destroy disease-causing proteins by harnessing the activity of specific E3 ligases. Nurix is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
1600 Sierra Point Pkwy, Brisbane, California, 94005
Website
www.nurixtx.com
Telephone
1 302 5310855
No of Employees
317
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NRIX (NASD)
Revenue (2024)
$84.0M
54%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-36.6%
(2024 vs 2023)
Market Cap*
$2.6B
Net Profit Margin (2024)
XYZ
11.3%
(2024 vs 2023)
* As of and is in US$
Nurix Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Bexobrutideg (NX-5948): Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia and Non-Hodgkin’s Lymphoma |
| Zelebrudomide (NX-2127): B-cell Malignancies |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In April, the company licensed an undisclosed program targeting a transcription factor for autoimmune diseases to Sanofi. |
| 2025 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration for Orphan Drug Designation to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia (WM). |
| 2024 | Regulatory Approval | In December, the company received approval from the US Food and Drug Administration for fast-track designation for NX-5948, a degrader of Bruton’s tyrosine kinase, to treat adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia. |
Competitor Comparison
| Key Parameters | Nurix Therapeutics Inc | Moderna Inc | Protagonist Therapeutics Inc | Kymera Therapeutics Inc | Cleave Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Brisbane | Cambridge | Newark | Watertown | San Jose |
| State/Province | California | Massachusetts | California | Massachusetts | California |
| No. of Employees | 317 | 4,700 | 100 | 238 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julia P. Gregory | Chairman | Executive Board | 2024 | 72 |
| Arthur T. Sands, M.D., Ph.D | Chief Executive Officer; President; Director | Executive Board | 2020 | 63 |
| Hans van Houte | Chief Financial Officer | Senior Management | 2020 | 59 |
| Christine Ring, Ph.D. | Chief Compliance Officer; Chief Legal Officer; Secretary | Senior Management | 2020 | 60 |
| Eric Schlezinger | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer